comparemela.com

Latest Breaking News On - Staci didner - Page 1 : comparemela.com

Quanterix to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Quanterix Announces Simoa Joint Laboratory with WuXi AppTec

Posted on 17276 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into an agreement to open a joint Simoa laboratory with WuXi AppTec to improve access to Quanterix’ industry leading biomarker testing and development offerings across China and the APAC market. The Simoa® Joint Lab is the strategic partnership between the two companies and will be established at WuXi AppTec’s Shanghai facility. The facility will leverage Quanterix’ ultra-sensitive Simoa HD-X Analyzers™, consumables resources and technical expertise to advance essential pre-clinical and clinical research in the region. “We’re excited to provide access to Simoa technology to the APAC region,” said Kevin Hrusovsky, Chairman, Chief Executive Officers and President of Quanterix. “This partnership enables us to offer even deeper support to ou

Quanterix Announces Simoa® Joint Laboratory with WuXi AppTec

Press release content from Business Wire. The AP news staff was not involved in its creation. Quanterix Announces Simoa® Joint Laboratory with WuXi AppTec February 12, 2021 GMT BILLERICA, Mass. (BUSINESS WIRE) Feb 12, 2021 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into an agreement to open a joint Simoa laboratory with WuXi AppTec to improve access to Quanterix’ industry leading biomarker testing and development offerings across China and the APAC market. The Simoa® Joint Lab is the strategic partnership between the two companies and will be established at WuXi AppTec’s Shanghai facility. The facility will leverage Quanterix’ ultra-sensitive Simoa HD-X Analyzers™, consumables resources and technical expertise to advance essential pre-clinical and clinical research in the region.

Quanterix Announces Closing of Public Offering Including Exercise of Underwriters Option to Purchase Additional Shares

Press release content from Business Wire. The AP news staff was not involved in its creation. Quanterix Announces Closing of Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares February 8, 2021 GMT BILLERICA, Mass. (BUSINESS WIRE) Feb 8, 2021 Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock at a public offering price of $70.00 per share, including 535,714 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $287.5 million.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.